Abstract: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.

Abstract: The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.

Abstract: The current invention presents enoyl-ACP reductase, an enzyme of the type II fatty acid synthesis pathway as a target for treating human malarias and other infectious diseases. We also present in the current invention, 2-thioxothiazolidin-4-ones as antimicrobial and antimalarial agents. We provide 2-thioxothiazolidin-4-ones as antimicrobial and antimalarial agents either alone or in combination with other known antimicrobial and antimalarial agents with or without added adjuvants or diluents or carriers.

Abstract: The invention relates to a fungicidally active compound of formula (I): where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, provided that the ring is not 1,2,3-triazole, the ring being substituted by groups R8, R9 and R10; X is a single or double bond; Y is O, S, N(R11) or (CR12R13)(CR14R15)m(CR16R17)n; m is 0 or 1; n is 0 or 1; and R1 to R17 each, independently, have a range of values; to the preparation of these compounds, to novel intermediates used in the preparation of these compounds, to agrochemical compositions which comprise at least one of the novel compounds as active ingredient, to the preparation of the compositions mentioned and to the use of the active ingredients or compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

Abstract: The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

Abstract: The present invention is a new stable extended release drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a matrix-forming agent, and a method for manufacturing same. When applied to acid-labile drugs like HMG-CoA reductase inhibitors, the resulting drug composition is stabilized and is characterized by an extended-release profile.

Abstract: The present invention provides processes to prepare atorvastatin calcium Form VI, pharmaceutical compositions comprising atorvastatin calcium Form VI, and processes to prepare said compositions. An aspect of the invention relates to atorvastatin calcium Form VI compositions having enhanced bioavailability when administered orally to humans.

Abstract: This invention describes a process for the production of ANHYDROUS active pharmaceutical ingredients (APIs); a process for the preparation of HYDRATED active pharmaceutical ingredients, a process for the preparation of sterile and stable injectable solutions, and their use, more specifically, APIs which are taxane derivatives, especially (2R,3S) 4-acetoxy-2-?-benzoyloxy-5?-20-epoxy-1,7-?-10-?-tri-hydroxy-9-oxo-tax-11-en-13?-il 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I); 4-acetoxy-2-?-benzoyloxy-5-?-20-epoxy-1, 7?-10-?-tri-hidroxy-9-oxo-tax-11-en-13?-il (2R,3S) 3-benzoylamino-2-hydroxy-3-phenylpropionate (II), and particularly 4-acetoxy-2-?-benzoyloxy-5?-20-epoxy-1,7-?-10-?-tri-hidroxy-9-oxo-tax-11-en-13?-il (2R,3S) 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate tri-hydrate (III).

Abstract: The invention relates to methods and materials involved in treating autoimmune conditions. In particular, the invention relates to methods and compounds (and compositions including the compounds) involved in treating, preventing, or delaying the onset of autoimmune conditions. The compounds include one or more isoprenoid units. The compounds can enhance NADPH oxidase activity.

Abstract: The present invention is directed to novel hexanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of hexanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of hexanoic acid derivatives of the invention. The invention further relates to the kits and other articles of manufacture for treating disease states associated with DPP-IV enzyme.

Abstract: The present invention relates to a pharmaceutical co-crystal comprising an active pharmaceutical ingredient and a co-crystal agent having the structure R1—C(?O)XH.

Abstract: The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These pathological conditions include, but are limited to, hypertension, in particular salt induced hypertension, and cardiovascular complications, including myocardial infarction, kidney dysfunction, diabetes, and inflammation. Further, the inventions relate to drug screening methods for providing additional therapeutic compounds.

Abstract: A method of treating animals to reduce the presence of annoying insects around the animal, help clean the animal's exterior, add luster and sheen to the animal's coat or hide, and provide stain repellency includes the application of a gelled composition to the exterior of an animal. The composition includes a nonionic primary surfactant comprising an ethoxylated sorbitol oleate, a nonionic secondary surfactant, and water The nonionic secondary surfactant is selected from the group consisting of linear ethoxylated secondary alcohols, polyoxyethylene ethers, ethoxylated sorbitan monolaurtes, ethoxylated fatty acid amides and ethoxylated fatty acids that contain about 7 moles to about 26 moles of ethylene oxide and comprise from about 20 to about 36 weight percent of said composition. The water is in a sufficient amount so that the nonionic primary and secondary surfactants together with the water form a gel.

Abstract: The invention relates to a method of treatment or prevention of drug addiction, in particular alcoholism, in humans, comprising administering to a subject, in need thereof, an effective amount of a Gly-T1 inhibitor, in particular N-methyl-N-[[(1R,2S)-1,2,3,4-tetrahydro-6-methoxy-1-phenyl-2-naphthalenyl]methyl glycine or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an optically active phthalamide derivative represented by the following formula (I): (wherein each of R1 and R2 represents H, optionally substituted C1-C6 alkyl, or C1-C6 alkoxycarbonyl; R3 represents C1-C6 alkyl; A represents H, C1-C6 alkyl, C3-C6 alkenyl, C3-C6 alkynyl, optionally substituted phenoxy C1-C6 alkyl, or the like; p represents 0, 1, 2, 3, or 4; q represents 0, 1, or 2; X represents halogen, CN, NH2, C1-C6 alkyl, C2-C6 alkenyl, C1-C6 alkylthio, or the like; m represents 0, 1, 2, 3, or 4; Y represents halogen, CN, NH2, C1-C6 alkyl, optionally substituted phenyl, or the like; n represents 1, 2, 3, 4, or 5; and each of Z1 and Z2 represents C—Y or N; and further X and Y may form a condensed ring together with carbon atoms adjacent thereto on a phenyl ring), a salt thereof, an agrohorticultural insecticide comprising the above derivative as an active ingredient, and a method of use thereof.

Abstract: Acyloxyalkyl carbamate prodrugs of ?-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of ?-amino acids and methods of using acyloxyalkyl carbamate prodrugs of ?-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of ?-amino acids suitable for oral administration using sustained release dosage forms are also disclosed.

Abstract: A method of treating Parkinson's Disease comprising intestinally administering to a patient in need thereof a pharmaceutically effective amount of a composition comprising levodopa and optionally carbidopa continuously over a period of greater than 16 hours.

Abstract: In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 ?g per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.

Abstract: Process for the treatment of human skin, by applying topically onto the skin a composition containing in a physiologically acceptable medium (i) at least one hydroxy acid selected from the ?-hydroxy acids, ?-hydroxy acids, ?-keto acids, ?-keto acids and mixtures thereof, and (ii) at least 5% by weight, relative to the total weight of the composition, of one or more surfactants containing an alkyl chain having from 6 to 16 carbon atoms.

Abstract: The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., berab1, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53.

Abstract: The present invention provides novel anthracene compounds according to the formulae (I) and (II) and also selected anthracene compound compounds. The present invention furthermore provides a process for preparing such anthracene compounds. Also provided are pharmaceutical formulations comprising these anthracene compounds. The anthracene compounds provided are particularly suitable for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions which can be treated by inhibiting tubulin polymerization and/or by inhibiting microtubuli-based motor proteins, in particular various tumor disorders.

Abstract: A method of inhibiting protein tyrosine phosphatase in a subject includes administering to the subject a therapeutically effective amount of at least one benzo-1,4-quinone, phenyl isothiazolone, or analog thereof to the subject.

Abstract: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.

Abstract: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.

Abstract: Compounds for controlling aquatic breeding insects including an ethoxylated alcohol with a carbon chain length of about 10 to about 24 carbon atoms and about 0 to about 16 moles of ethylene oxide per mole of alcohol, where the carbon chain is linear or branched with an alkyl group are provided. Methods for making branched alcohol ethoxylated compounds and linear secondary alcohol ethoxylated compounds are also provided. Methods for controlling insects with the compounds are also provided.

Abstract: The present invention relates to a liquid dual phase cosmetic or pharmaceutical composition comprising an oil phase and an aqueous phase, the composition containing as a demixing agent a film forming agent such as polyvinylpyrrolidone and derivatives thereof. The compositions of the invention are particularly useful as makeup removers.

Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.

Abstract: A fatty acid ester of pentaerythritol, a pentaerythritol oligomer, or mixtures thereof, where the fatty acid has 6 to 22 carbon atoms, and the ester contains less than 0.3% by weight C17 fatty acid acyl groups and has a melting point of at least 30° C. is provided. A process for the production of a C16/C18 fatty acid pentaerythritol ester including (A) providing about 1.8 to about 2.2 mol of a fatty acid mixture per mol of pentaerythritol; (B) esterifying component (A) at temperatures ranging from about 180° C. to about 250° C. in an inert gas atmosphere in the absence of solvent to form a reaction mixture; (C) stirring the reaction mixture in vacuo until it has an acid value of less than 1 and an OH value of 145 to 158 is provided. A cosmetic and/or pharmaceutical composition including the above-described ester is also provided.

Abstract: Use of a compound having a hydrophobic moiety attached to a hydrophilic moiety, wherein the hydrophilic moiety comprises a ?-keto acid group and the hydrophobic moiety is attached via a bond from a carbon or an oxygen of the hydrophobic moiety to a carbon of the ?-keto acid group, provided that the ?-carbon of the ?-keto acid group does not form part of a carboxyl or ester group, or a salt thereof, as a surfactant. A dispersion comprising said surfactant as a dispersing agent. A microemulsion comprising said surfactant. A method for breaking a dispersion comprising said surfactant as a dispersing agent, said method comprising the steps of a) providing said dispersion at a temperature where it is substantially stable; and b) setting the temperature of said dispersion, so as to achieve a desired decomposition rate of the surfactant. A method for reducing the surface tension between a liquid and another phase, comprising adding to the liquid said surfactant.

Abstract: The subject invention relates to surfactant compositions of gemini surfactants and co-amphiphile(s), to a process for preparing such compositions, and to their uses, especially as emulsifiers and dispersants.

Abstract: A method and device for producing a finely divided dispersion of solids having a mean particle size of 10 nm to 10 µm, in which at least two flows of a predispersion are sprayed by means of pumps, preferably high-pressure pumps, through one nozzle each into a grinding chamber enclosed by a reactor housing onto a collision point, wherein the grinding chamber is flooded with the predispersion and the finaly divided dispersion is removed from the grinding chamber by the overpressure of the predispersion continuing to flow into the grinding chamber.

Abstract: The present invention relates to a process for the conversion of cobalt(II)hydroxide into cobalt(III)oxidehydroxide (CoOOH) by reaction of the cobalt(II)hydroxide with oxygen in the presence of certain metal compounds. The invention further relates to the use of cobalt(III)oxidehydroxide thus prepared in the preparation of catalysts or catalysts precursors, especially catalysts or catalyst precursors for the conversion of synthesis gas into normally liquid and normally solid hydrocarbons and to normally liquid or solid hydrocarbons, optionally after additional hydrotreatment, obtained in such a conversion process.

Abstract: The present invention provides a process for the hydroformylation of ethylenically unsaturated compounds, which process comprises reacting said ethylenically unsaturated compound with carbon monoxide and hydrogen, in the presence of a catalyst system and a solvent, the catalyst system obtainable by combining: a) a metal of Group VIII or a compound thereof; and b) a bidentate phosphine, the process characterised in that a chlorine moiety is present in at least one of the said Group VIII metal compound or said solvent.

Abstract: In accordance with one embodiment of the present disclosure, a method of producing alcohol includes dispersing a catalyst in a supercritical fluid and causing carbon monoxide and hydrogen to contact the dispersed catalyst, whereby a reaction occurs to produce the alcohol.

Abstract: Process to optimize the yield of gas oils from a Fischer-Tropsch derived feed by performing the following steps: (a) performing a hydroconversion/hydroisomerisation step on part of the Fischer-Tropsch derived feed; (b) performing a hydroconversion/hydroisomerisation step on another part of the Fischer-Tropsch feed at a conversion greater than the conversion in step (a); and (c) isolating by means of distillation a gas oil fraction from the two reaction products obtained in steps (a) and (b).

Abstract: A method of: introducing hydrogen and a feed gas containing at least 50 vol % carbon dioxide into a reactor containing a Fischer-Tropsch catalyst; and heating the hydrogen and carbon dioxide to a temperature of at least about 190° C. to produce hydrocarbons in the reactor. An apparatus having: a reaction vessel for containing a Fischer-Tropsch catalyst, capable of heating gases to at least about 190° C.; a hydrogen delivery system feeding into the reaction vessel; a carbon dioxide delivery system for delivering a feed gas containing at least 50 vol % carbon dioxide feeding into the reaction vessel; and a trap for collecting hydrocarbons generated in the reaction vessel.

Abstract: The invention concerns fluoropolymers comprising at least one repeat unit of formula (I): wherein: groups X and Y, identical or different, represent H or F; group Z represents F or a perfluorinated alkyl group; group W represents CH2O or CF2O or CO2; group Ar represents a divalent group including at least one optionally substituted carbon-containing aromatic cycle; group Q represents a single bond, (CF2)n with 1?n?10, or C2F4OC2F4; group G represents a cation exchanging group, preferably selected among: SO2R1, with R1 representing OH, F or Cl; or P(?O) (OR2)2 with R2 representing H or an optionally substituted alkyl group; or CO2H and having ion exchange capacity not less than 0.5 meq/g polymer. The method of synthesis, the membranes obtained using these polymers and the fuel cell systems containing such membranes are also part of the invention.

Abstract: There is provided a modified ion exchange resin catalyst which exhibits higher bisphenols selectivity than the conventional modified ion exchange resins in processes wherein bisphenols are produced by reacting a phenolic compound with ketones, and to provide such a process for producing bisphenols.

Abstract: A resin composition and an article formed therefrom are disclosed. The resin composition comprises a halogenated polyol, a brominated polyol different from the halogenated polyol, and a flame retardant. The resin composition may further comprise other components, such as supplemental polyols, catalysts, adhesion promoters, surfactants, blowing agents, additives, or combinations thereof. The article comprises the reaction product of an isocyanate, the halogenated polyol, and the brominated polyol in the presence of the flame retardant, a blowing agent, and optionally, one of more of the other components. Typically, the article is defined as a polyurethane foam. The article exceeds Class I flammability requirements, such as flame spread index, smoke density, and convective flame spread parameter according to ASTM E-84 and FM 4880 testing.

Abstract: Both flexible and rigid foams may be prepared by reacting di- or polyisocyanates with organopolysiloxanes which are prepared by reaction of silanol-terminated organopolysiloxanes with organosilicon compounds containing alkyleneoxy or alkylenamino groups bonded on both ends to silicon, thus resulting in organopolysiloxanes having 95% or more of aminoalkyl or hydroxyalkyl terminal groups.

Abstract: The present invention relates to a photosensitive resin composition, and more particularly, to a photosensitive resin composition for forming an over coating layer of a color filter. The photosensitive resin composition according to the present invention includes a UV absorber. The photosensitive resin composition according to the present invention adjusts line width and height of a pattern without difficulty, forms a linear pattern, provides good transmittance and is adequate to form the over coating layer of the color filter.

Abstract: A photopolymerizable composition is herein provided and it comprises the following components: a) a photopolymerizable compound; b) a photopolymerization initiator; and c) organic pigment fine particles on which the polymer of a polymerizable compound is immobilized, whose volume average particle size: Mv is not more than 50 nm, and which has a ratio: Mv/Mn (wherein Mv represents the volume average particle size of the pigment fine particles and Mn represents the number average particle size thereof) ranging from 1 to 1.5. The photopolymerizable composition can be used in various applications such as the 3-dimensional optical moulding or holography, a plate material for forming lithographic printing plate, image-forming materials such as color proof, photoresists and color filters, ink and photocurable resin materials such as adhesives.

Abstract: The invention relates to a hot-melt composition, especially for using as an absorbent medical or cosmetic article, preferably as a wound dressing, and containing (a) a chemically cross-linked polymer matrix, and (b) hydrocolloids which are embedded in the chemically cross-linked polymer matrix. The inventive composition can be obtained by processing a melt in a hot melt method, said melt having a melting viscosity of less than 100 Pa*s, preferably less than 75 Pa*s, and especially preferably less than 50 Pa*s, at a processing temperature of less than 150° C., preferably less than 140° C., and especially preferably less than 130° C.

Abstract: A one step system for hoof repair material that cures upon exposure to light. Found is a urethane solution that contains polymerization initiators so that exposure to visible light induces the cure.

Abstract: The present invention provides a process for producing a polysilsesquioxane graft polymer (1) which includes applying ionizing radiation or heat to a mixture including a polysilsesquioxane compound (2) and a vinyl compound (3), a polysilsesquioxane compound including an iniferter group, and a pressure-sensitive adhesive and a pressure-sensitive adhesive sheet using the polymer. According to the present invention, a process for producing a polysilsesquioxane graft polymer which may be used as a pressure-sensitive adhesive exhibiting excellent heat resistance and cohesive force, and the like are provided. In the formula, A represents a linking group, R1 represents a hydrocarbon group which may have a substituent, R2 represents a hydrogen atom or the like, R3 represents a polar group or the like, R4 represents a hydrogen atom or the like, k1 to k3 represent arbitrary positive integers, 1 to n represent zero or an arbitrary positive integer (excluding the case where “m=n=0”), and Q represents an iniferter group.

Abstract: The invention relates to a dental composition comprising a) halogenated aryl alkyl ether component (A) comprising at least 1 aryl alkyl ether moiety, at least 1 halogen atom attached to each aryl residue of the aryl alkyl ether moieties, at least 2 unsaturated moieties, b) Si—H functional component (B), c) initiator (C), d) optionally filler (D), and e) optionally component (E) selected from modifiers, dyes, pigments, thixotropic agents, flow improvers, polymeric thickness, surfactants, odorous substances, diluting agent(s) and flavourings.

Abstract: A method of repairing a flesh wound to, substantially, a pre-wound condition is provided. The method includes the steps of providing a composition prepared by a certain process and applying an amount of the composition to the wound sufficient to substantially cover the wound, wherein said application occurs about twice daily for a period of at least about ten days. The process for preparing the composition includes the steps of providing an ingredient consisting essentially of eggs; mixing the eggs until they form a substantially uniform mixture; adding the mixture to a cooking vessel; heating the cooking vessel until the mixture comprises a black liquid component; agitating the mixture during heating; collecting the black liquid component; and cooling the black liquid component. A method of treating a flesh wound is also provided, as well as a method of preparing a composition for treatment of a flesh wound.

Abstract: Devices formed of or including biocompatible polyhydroxyalkanoates are provided with controlled degradation rates, preferably less than one year under physiological conditions. Preferred devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws (including interference screws), bone plates and bone plating systems, surgical mesh, repair patches, slings, cardiovascular patches, orthopedic pins (including bone filling augmentation material), adhesion barriers, stents, guided tissue repair/regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices, atrial septal defect repair devices, pericardial patches, bulking and filling agents, vein valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion cages, skin substitutes, dural substitutes, bone graft substitutes, bone dowels, wound dressings, and hemostats.

Abstract: A pigment contains one or more substantially spherical-shaped beads. Each substantially spherical-shaped bead includes one or more high aspect ratio particles encapsulated within an encapsulating material. Resinous compositions containing this pigment and a plastic, for example a polycarbonate, have a flowline-free colored, sparkling and/or metallescent appearance.

Abstract: Inverse emulsions, useful in applications such as cosmetics, are those wherein the weight ratio between the aqueous phase and the organic phase is from 4:1 to 2:1 and containing from 20 to 70% by weight of an acrylic polymer comprising monomeric units deriving from: i) 2-acrylamido-2-methylpropanesulfonic acid; ii) at least one cationic acrylic monomer of formula I: wherein R1 is hydrogen or methyl; R2, R3, R4 are, one independently of the others, hydrogen or C1-C4 alkyl; Y is NH or O; A is a C1-C6 alkylene; X is an anion; iii) acrylic or methacrylic acid; iv) at least one polyfunctional monomer, the inverse emulsion being characterized by the fact that in the polymer the monomeric units deriving from 2-acrylamido-2-methylpropanesulfonic acid represent from 1% to 29% molar of the total monomers i), ii) and iii).